Maximus (NYSE:MMS) Updates FY 2022 Earnings Guidance

Maximus (NYSE:MMS) issued an update on its FY 2022 earnings guidance on Thursday morning. The company provided earnings per share guidance of $5.070-$5.370 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.450. The company issued revenue guidance of $4.40 billion-$4.60 billion, compared to the consensus revenue estimate of $4.12 billion.

Shares of MMS traded down $0.03 during midday trading on Thursday, reaching $80.72. 252,763 shares of the stock were exchanged, compared to its average volume of 309,371. The business’s 50-day moving average price is $84.10 and its 200 day moving average price is $86.66. The company has a debt-to-equity ratio of 0.97, a current ratio of 1.37 and a quick ratio of 1.37. Maximus has a twelve month low of $67.65 and a twelve month high of $96.05. The company has a market capitalization of $5.00 billion, a price-to-earnings ratio of 17.32 and a beta of 0.76.

Maximus (NYSE:MMS) last posted its earnings results on Thursday, November 18th. The health services provider reported $1.08 EPS for the quarter, topping the Zacks’ consensus estimate of $0.87 by $0.21. Maximus had a return on equity of 22.53% and a net margin of 6.84%. The business had revenue of $1.11 billion for the quarter, compared to analysts’ expectations of $1.08 billion. During the same quarter in the previous year, the firm earned $1.02 earnings per share. The business’s revenue was up 19.7% compared to the same quarter last year. As a group, equities research analysts expect that Maximus will post 4.15 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, November 30th. Stockholders of record on Monday, November 15th will be given a dividend of $0.28 per share. This represents a $1.12 dividend on an annualized basis and a dividend yield of 1.39%. The ex-dividend date is Friday, November 12th. Maximus’s dividend payout ratio (DPR) is currently 24.03%.

Separately, Zacks Investment Research cut Maximus from a buy rating to a hold rating and set a $85.00 target price on the stock. in a research report on Tuesday.

In other Maximus news, Vice Chairman Richard A. Montoni sold 6,234 shares of the business’s stock in a transaction that occurred on Thursday, September 30th. The stock was sold at an average price of $83.20, for a total transaction of $518,668.80. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, General Counsel David Francis sold 5,788 shares of the business’s stock in a transaction that occurred on Thursday, September 30th. The stock was sold at an average price of $83.20, for a total value of $481,561.60. The disclosure for this sale can be found here. Insiders sold a total of 35,155 shares of company stock worth $2,896,362 in the last 90 days. 1.90% of the stock is currently owned by insiders.

An institutional investor recently raised its position in Maximus stock. Jane Street Group LLC lifted its position in shares of Maximus, Inc. (NYSE:MMS) by 4.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,742 shares of the health services provider’s stock after acquiring an additional 806 shares during the quarter. Jane Street Group LLC’s holdings in Maximus were worth $1,559,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 94.30% of the company’s stock.

Maximus Company Profile

MAXIMUS, Inc engages in the operation of government and human services programs. It operates through the following segments: U.S. Services; U.S. Federal Services; and Outside the U.S. The U.S. Services segment offers a variety of business process services, and appeals and assessments for state, provincial and national government programs.

Featured Article: Differences Between Momentum Investing and Long Term Investing

Earnings History and Estimates for Maximus (NYSE:MMS)

Receive News & Ratings for Maximus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maximus and related companies with's FREE daily email newsletter.